Down syndrome long-term study after leukemia treatment
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 6 and 39 years old when you join
- Have Down syndrome confirmed by your doctor (one of three types is okay)
- Have survived acute leukemia: ALL or AML (including myeloid leukemia linked to Down syndrome)
- Finish all leukemia treatment at least 36 months (3 years) before joining
- No history of bone marrow/stem cell transplant for treatment of your leukemia
- Live in a way that allows you and a parent/guardian to complete study forms in English or Spanish
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
This study is looking at how the immune system changes over time in people with Down syndrome, and how it may be affected by removal of the thymus gland. The goal is to understand why people with Down syndrome may age faster or have different immune health.
This research study aims to better understand Down syndrome by collecting health information, family history, and sometimes brain imaging or sleep data from children and adults with Down syndrome and their families. The goal is to advance knowledge that could improve health and development for people with Down syndrome.
This trial tests a treatment plan for children with Down syndrome who have been diagnosed with acute myeloid leukemia (AML) or a related bone marrow condition. The goal is to see how well the therapy works and to help guide doctors in choosing the best approach.
This study looks at two childhood blood disorders—myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML). The goal is to describe how these conditions work in children and better understand them over time.
This study collects information from people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that developed after cancer treatment. It does not test a new drug but helps doctors learn more about these conditions.
Hear when a new Down Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.